Coherus Oncology
CHRS
189 hedge funds and large institutions have $1.08B invested in Coherus Oncology in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 82 increasing their positions, 58 reducing their positions, and 37 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 58
7.51% less ownership
Funds ownership: 110.32% → 102.81% (-7.5%)
8% less funds holding
Funds holding: 205 → 189 (-16)
8% less capital invested
Capital invested by funds: $1.17B → $1.08B (-$96.6M)
13% less call options, than puts
Call options by funds: $1.54M | Put options by funds: $1.77M
43% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 37
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$12.7M |
| 2 |
BlackRock
New York
|
+$11.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.37M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.25M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$11.4M |
| 2 |
Goldman Sachs
New York
|
-$10.7M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$9.64M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$8.87M |
| 5 |
SCM
Sio Capital Management
New York
|
-$6.15M |
CHRS Hedge Fund Activity: Q2 2021 in Review
189 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2021, worth a combined $1.08B — down 8.2% from $1.17B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CHRS and 21 opened new positions — a net loss of 16 holders — while 58 trimmed existing stakes and 82 added.
The largest buyer was JP Morgan Chase, adding an estimated $12.7M. The largest seller was Candriam SCA, exiting entirely with an estimated $11.4M sold.
- 189 institutional investors held Coherus Oncology (CHRS) as of Q2 2021, down from 205 in Q1 2021.
- Funds reported $1.08B of Coherus Oncology stock for Q2 2021, down 8.2% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q2 2021 and 37 closed out, a net change of -16 holders.
- The largest Coherus Oncology buyer in Q2 2021 was JP Morgan Chase, an estimated $12.7M added.
- The largest Coherus Oncology seller in Q2 2021 was Candriam SCA, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2021.